	US 12,466,866 B2
	Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
Carole Guillonneau, La Chevrolière (FR); Ignacio Anegon, Nantes (FR); Erwan Mortier, Nantes (FR); and Agnès Quemener, Nantes (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Paris, FRANCE, Paris (FR); and UNIVERSITÉ DE NANTES, Nantes (FR)
Appl. No. 17/422,556
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ DE NANTES, Nantes (FR)
PCT Filed Jan. 15, 2020, PCT No. PCT/EP2020/050920 § 371(c)(1), (2) Date Jul. 13, 2021, PCT Pub. No. WO2020/148338, PCT Pub. Date Jul. 23, 2020.
Claims priority of application No. 19305046 (EP), filed on Jan. 15, 2019.
Prior Publication US 2022/0098264 A1, Mar. 31, 2022
Int. Cl. A61K 38/20 (2006.01); C07K 14/54 (2006.01); C12N 5/0786 (2010.01); A61K 38/00 (2006.01)

CPC C07K 14/54 (2013.01) [A61K 38/20 (2013.01); C12N 5/0645 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01); C12N 2501/2334 (2013.01); C12N 2506/115 (2013.01)]

12 Claims

1. A mutated interleukin-34 (IL-34) polypeptide comprising

an amino acid sequence ranging from the asparagine residue at position 21 of SEQ ID NO: 1 to the proline residue at position 242 of SEQ ID NO: 1, wherein one or more mutations have been introduced, said one or more mutations being selected from the group consisting of:

a substitution of the serine residue at position 100 by a phenylalanine residue (S100F),

a substitution of the threonine residue at position 36 by a tyrosine residue (T36Y),

a substitution of the glutamine residue at position 131 by a phenylalanine residue (Q131F),

a substitution of the threonine residue at position 36 by a tryptophan residue (T36W),

a substitution of the threonine residue at position 36 by a phenylalanine residue (T36F),

a substitution of the histidine residue at position 56 and of the glycine residue at position 112 by a cysteine residue (H56C and G112C), and

combinations thereof.